Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × INDUSTRY × Ovarian Cancer Metastatic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 73 Neoplasms 70 Breast Neoplasms 69 Leukemia, Myeloid, Acute 37 Recurrence 31 Neoplasm Metastasis 28 Colorectal Neoplasms 28 Prostatic Neoplasms 26 Pancreatic Neoplasms 23 Multiple Myeloma 22 Melanoma 22 Lymphoma, Non-Hodgkin 22 Lymphoma 22 Carcinoma, Hepatocellular 22 Lung Neoplasms 21 Leukemia, Lymphocytic, Chronic, B-Cell 20 Ovarian Neoplasms 19 Carcinoma, Renal Cell 19 Myelodysplastic Syndromes 18 Lymphoma, Large B-Cell, Diffuse 18 Stomach Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 17 Lymphoma, Follicular 17 Urinary Bladder Neoplasms 16 Precursor Cell Lymphoblastic Leukemia-Lymphoma 16 Head and Neck Neoplasms 16 Leukemia 14 Uterine Cervical Neoplasms 12 Hematologic Neoplasms 11 Glioblastoma 11

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡